The latest price target for Iovance Biotherapeutics (NASDAQ:IOVA) was reported by HC Wainwright & Co. on August 12, 2024. The analyst firm set a price target for $32.00 expecting IOVA to rise to within 12 months (a possible 207.40% upside). 25 analyst firms have reported ratings in the last year.

The latest analyst rating for Iovance Biotherapeutics (NASDAQ:IOVA) was provided by HC Wainwright & Co., and Iovance Biotherapeutics reiterated their buy rating.

The last upgrade for Iovance Biotherapeutics Inc happened on May 30, 2023 when Wells Fargo raised their price target to $17. Wells Fargo previously had an equal-weight for Iovance Biotherapeutics Inc.

The last downgrade for Iovance Biotherapeutics Inc happened on July 29, 2024 when Piper Sandler changed their price target from $19 to $10 for Iovance Biotherapeutics Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Iovance Biotherapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Iovance Biotherapeutics was filed on August 12, 2024 so you should expect the next rating to be made available sometime around August 12, 2025.

While ratings are subjective and will change, the latest Iovance Biotherapeutics (IOVA) rating was a reiterated with a price target of $32.00 to $32.00. The current price Iovance Biotherapeutics (IOVA) is trading at is $10.41, which is out of the analyst’s predicted range.